Telomir Pharmaceuticals, Inc. (NASDAQ:TELO – Get Free Report) shares fell 2.4% on Thursday . The company traded as low as $6.51 and last traded at $6.80. 9,254 shares changed hands during trading, a decline of 86% from the average session volume of 67,604 shares. The stock had previously closed at $6.97.
Telomir Pharmaceuticals Stock Performance
The firm has a 50 day moving average of $7.33.
Telomir Pharmaceuticals Company Profile
Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.
Featured Stories
- Five stocks we like better than Telomir Pharmaceuticals
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- MarketBeat Week in Review – 4/22 – 4/26
- How to Evaluate a Stock Before Buying
- 3 Stocks Leading the U.S. Agriculture Comeback
- Dividend Payout Ratio Calculator
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Telomir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telomir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.